March 04, 2026 07:48 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Defiant silence: Iran women’s team refuses anthem days after Khamenei’s death | 'You’ll find out soon': Trump hints at massive retaliation after Riyadh attack, says ‘boots on ground’ may not be needed | Iran claims Netanyahu's office targeted in 'surprise missile attacks' | India, Canada to host renewable energy summit as Modi, Carney push to deepen bilateral ties | Gold, silver surge as Middle East conflict sparks safe-haven buying | Middle East tension: Several US warplanes crash in Kuwait, says Defence Ministry | Indian defence shares jump as West Asia conflict triggers investor rush | Modi-Carney talks signal fresh start as India, Canada push to revive trade pact and strategic partnership | IDF strikes Hezbollah targets in Lebanon after projectile fire toward Northern Israel; 31 killed | Israeli airstrikes hit Tehran’s Gandhi Hospital amid Middle East conflict
Stock Market
Representational Photo: ChatGPT

Bloodbath on Dalal Street! Sensex crashes over 700 points, Nifty down 200 points amid market panic

| @indiablooms | Jan 08, 2026, at 02:08 pm

Mumbai/IBNS: The Indian stock market witnessed a sharp sell-off on Thursday, with the BSE Sensex plummeting over 700 points and the NSE Nifty 50 sliding more than 200 points, media reports said.

The indices remained under pressure throughout the morning session, with Sensex touching an intraday low of 84,230.

Among the notable laggards in the Nifty 500 were Signature Global, Hindustan Zinc, National Aluminium, NMDC, Hindustan Copper, JSL and GMDC.

At around 1:30 pm, Punjab National Bank shares fell 2.13%, while Apex Frozen Foods plunged 7.56%, intensifying the market slide.

In the morning, shares of Panacea Biotec Ltd. surged around 9 per cent on Thursday after the pharmaceutical and vaccine maker announced the completion of enrollment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

The company has enrolled a total of 10,335 participants in the late-stage trial, marking a key milestone in the development of India’s indigenous dengue vaccine.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm